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Objectives This study sought to investigate into the biologically plausible interaction between the common haptoglobin (Hp)
polymorphism rs#72294371 and glycosylated hemoglobin (HbA1c) on risk of coronary heart disease (CHD).
Background Studies of the association between the Hp polymorphism and CHD report inconsistent results. Individuals with the
Hp2-2 genotype produce Hp proteins with an impaired ability to prevent oxidative injury caused by elevated HbA1c.
Methods HbA1c concentration and Hp genotype were determined for 407 CHD cases matched 1:1 to controls (from the
NHS [Nurses’ Health Study]) and in a replication cohort of 2,070 individuals who served as the nontreatment
group in the ICARE (Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment)
study, with 29 CHD events during follow-up. Multivariate models were adjusted for lifestyle and CHD risk factors
as appropriate. A pooled analysis was conducted of NHS, ICARE, and the 1 previously published analysis (a car-
diovascular disease case-control sample from the Strong Heart Study).
Results In the NHS, Hp2-2 genotype (39% frequency) was strongly related to CHD risk only among individuals with ele-
vated HbA1c (6.5%), an association that was similar in the ICARE trial and the Strong Heart Study. In a pooled
analysis, participants with both the Hp2-2 genotype and elevated HbA1c had a relative risk of 7.90 (95% confi-
dence interval: 4.43 to 14.10) for CHD compared with participants with both an Hp1 allele and HbA1c 6.5%
(p for interaction  0.004), whereas the Hp2-2 genotype with HbA1c 6.5% was not associated with risk (rela-
tive risk: 1.34 [95% confidence interval: 0.73 to 2.46]).
Conclusions Hp genotype was a significant predictor of CHD among individuals with elevated HbA1c. (J Am Coll Cardiol
2013;61:728–37) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.063t
sHaptoglobin (Hp) is an abundant plasma protein that
protects against oxidative damage mediated by extracorpus-
cular hemoglobin (1). A common polymorphism
(rs#72294371) exists at the Hp locus and consists of 2
lleles, denoted 1 and 2, that are defined by the absence or
resence of a 1700 base pair partial intragenic duplication,
hus forming 3 possible Hp genotypes (1-1, 2-1, and 2-2)
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grants CA87969, CA49449, HL34594, DK085226, and DK085226 and by a
Canadian Institutes of Health Research (Ottawa, Ontario) Postdoctoral Fellow-
ship to Dr. Cahill. Dr. Levy is the author of a patent owned by his university
regarding use of haptoglobin genotypes to predict susceptibility to cardiovascular
disease in individuals with diabetes. Dr. Levy also presently serves as a scientific
consultant for Haptocure, which has licensed the aforementioned patent from his
university. Dr. Blum is a cofounder and CEO of Haptocure. All other authors
have reported that they have no relationships relevant to the contents of this paper
to disclose.Manuscript received August 1, 2012; revised manuscript received September 20,
2012, accepted September 27, 2012.
w
w
m
m
H
c
w
s
M
C
p
w
t
t
d
p
M
b
t
m
m
w
f
i
v
m
t
b
T
t
p
C
H
a
C
(
C
t
N
t
w
d
c
S
v
a
w
a
p
v
g
s
t
(
r
n
b
C
p
o
t
w
H
r
g
T
e
w
r

g
b
f
r
(
f
l
e
h
t
C
729JACC Vol. 61, No. 7, 2013 Cahill et al.
February 19, 2013:728–37 Haptoglobin, HbA1c, and Coronary Heart Diseaseagainst infectious disease, but in modern times, it may
confer increased risk of several noninfectious, inflammatory,
and chronic disease complications (3). Compared with the
Hp1-1 genotype, and to a lesser extent the intermediary
Hp2-1 genotype, individuals with the Hp2-2 genotype pro-
duce a protein that is dysfunctional in protecting against
hemoglobin-driven oxidative damage, leading to increased in-
flammation and oxidative stress, reduced ability of high-density
lipoprotein (HDL) to promote reverse cholesterol efflux, and
plaque instability in several in vitro and in vivo systems (4–8).
This dysfunction in the Hp2-2 protein is accentuated when
hemoglobin is glycosylated (6).
The Hp2-2 genotype has been consistently associated
with increased risk of cardiovascular complications, such as
myocardial infarction (MI), among individuals with type 2
diabetes (2,9). However, the relationship between Hp ge-
notype and coronary heart disease (CHD) in people without
diabetes is unclear and controversial (2,10). The impact of
maintaining strict glycemic control on the prevention of
cardiovascular complications in individuals with type 2
diabetes is also inconsistent (11,12). A possible explanation
for this inconsistency is that strict glycemic control may only
be beneficial in reducing CHD risk in a subset of individuals
most susceptible to vascular damage from hyperglycemia,
such as those with the Hp2-2 genotype.
We explored the potential statistical interaction between
the Hp genotype and glycemia, as quantified by glycosylated
hemoglobin (HbA1c) concentration, on the risk of CHD
ithin 1 large prospective cohort of apparently healthy
omen. We then replicated this analysis in a second and
ore focused cohort of individuals with diabetes to deter-
ine if individuals with the Hp2-2 genotype and elevated
bA1c are at increased risk of incident CHD. Finally, we
onducted a meta-analysis of results from these 2 cohorts
ith those from a previously published nested case-control
tudy of Hp genotype and cardiovascular disease (CVD).
ethods
ohort: the NHS. The NHS (Nurses’ Health Study) is a
rospective cohort of 121,700 female U.S. registered nurses
ho were aged 30 to 55 years at baseline in 1976. Informa-
ion on anthropometric and lifestyle factors is obtained
hrough self-administered questionnaires every 2 years and
iet every 4 years. From 1989 to 1990, a blood sample was
rovided by 32,826 women. Women who had an incident
I (n  343) or fatal CHD (n  64) between the date of
lood draw and June 2004 were identified and matched 1:1
o controls for age, smoking status, fasting status, and
onth of blood draw, as described elsewhere (13). The
ajority (96%) of nurses in this case-control sample are
hite. Anthropometric and lifestyle variables were derived
rom the questionnaire administered in 1990, with missing
nformation substituted from previous questionnaires. The
alidity of the questionnaires and the reproducibility of the
easurements have been reported previously (14,15), as has (he measurement of the standard
iochemical risk variables (13).
he institutional review board of
he Brigham and Women’s Hos-
ital and the Human Subjects
ommittee Review Board of the
arvard School of Public Health
pproved the study protocol.
ohort:theICAREstudy. ICARE
Prevention of Cardiovascular
omplications in Diabetic Pa-
ients With Vitamin E Treatment;
CT00220831) is a large clinical
rial of vitamin E in participants
ith type 2 diabetes; it was con-
ucted within 47 primary health-
are clinics of the Clalit Health
ervices in Israel, as described pre-
iously (16). These participants were white men and women
ged 22 to 95 years with type 2 diabetes at baseline who
ere enrolled in the Clalit Health Plan Diabetes Registry
nd were followed up prospectively for CHD events. Only
articipants with the Hp2-2 genotype were randomized to receive
itamin E or placebo; participants with the Hp1-1 and Hp2-1
enotypes were not included in the randomization. The ICARE
ample of participants included in the current analysis consists of
he 2,070 individuals remaining who did not receive vitamin E
the untreated Hp1-1 and Hp2-1 patients and the Hp2-2 patients
eceiving placebo). The vitamin E–treated Hp2-2 patients were
ot included in the current analysis to avoid introducing bias
ecause these patients have been shown to have lower risk of
HD due to the administered vitamin E. The study
rotocol was approved by the independent ethics committee
f the Carmel Medical Center in Clalit Health Services and
he Israeli Ministry of Health. All participants provided
ritten informed consent.
p typing. Hp genotype, recently given the identifier
s#72294371 (17), was determined in both cohorts by using
el electrophoresis of hemoglobin-enriched serum (18).
his procedure produces a signature banding pattern for
ach Hp type and has been shown to corroborate completely
ith the Hp genotype determined by polymerase chain
eaction (19). An unambiguous Hp type was obtained on
99.5% of all samples. A pilot study to test the Hp
enotyping method in the NHS found 99% concordance
etween duplicate samples of 76 individuals. Genotype
requencies in the NHS were in Hardy-Weinberg equilib-
ium in the whole sample (p  0.49) and also within cases
p  0.84) and controls (p  0.52) separately. Genotype
requencies in ICARE were not in Hardy-Weinberg equi-
ibrium, but this was driven by the study design that
xcluded one half of the Hp2-2 participants because they
ad been given vitamin E treatment in the ICARE clinical
rial.
HD case assessment. As previously described in NHS
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
HbA1c  glycosylated
hemoglobin
HDL  high-density
lipoprotein
Hp  haptoglobin
LDL  low-density
lipoprotein
MI  myocardial infarction
RR  relative risk20) and ICARE (16), CHD was similarly defined in the 2
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Health Organization criteria (21) (symptoms plus either
diagnostic electrocardiographic changes or altered levels of
cardiac enzymes) were used to diagnose CHD. Nonfatal
NHS events were confirmed through review of medical
records, with deaths confirmed by using medical records,
the National Death Index, and from death certificates. All
information was reviewed by NHS investigators who deter-
mined the primary cause of death. ICARE cases were
ascertained by reviewing all hospitalizations of study partic-
ipants; the hospitalization discharge summary was used for
adjudication of events by a panel of physicians. MI was
defined by the typical rise and fall of serum markers of
myocardial necrosis with at least 1 of the following:
1) typical ischemic symptoms; 2) development of pathologic
Q waves on the electrocardiogram; or 3) electrocardio-
graphic changes diagnostic of ischemia. All death cases were
ascertained by using the national death registry. For out-of-
hospital deaths, adjudication was based on interviews with
the participant’s physician and family.
Statistical analysis. Participant characteristics were com-
pared between genotypes by using a general linear model for
continuous variables and chi-square tests for categorical
variables, unless there was a cell with n  5, in which case
the Fisher exact test was used. For skewed variables, p values
from log-transformed analyses, geometric means, and
reverse-transformed 95% confidence intervals were re-
ported. All analyses were conducted by using SAS version
9.1 (SAS Institute, Inc., Cary, North Carolina) at a 2-tailed
alpha level of 0.05.
Because of the nested case-control study design, relative
risks (RRs) of CHD for the NHS were estimated by using
incidence rate ratios from logistic regression with adjust-
ment for the matching factors. In the prospective ICARE
cohort, Cox proportional hazards models were used, with
days in study as the time-dependent variable to estimate
hazard ratios as estimates of RR. For the NHS, uncondi-
tional logistic regression was used to allow for maximum
statistical power in stratified analyses and because 6 partic-
ipants ended up unmatched due to missing data for their
match. Because of limited power to test for interactions
across strata of Hp genotype (due to the Hp1-1 genotype
frequency [15%]), we combined the Hp1-1 genotype with
the Hp 2-1 genotype for these analyses.
In addition to matching factors (age, smoking, fasting
status, and month of blood draw), NHS analyses were
adjusted for body mass index, alcohol intake, diabetes,
history of hypercholesterolemia, and history of hyperten-
sion. The following variables were considered as potential
covariates for the NHS analysis but ultimately were not
included in the model because they did not influence the
association: marital status, physical activity, cholesterol-
lowering medication use, insulin and oral diabetes medica-
tion use, menopausal status, hormone therapy, and parental
MI at 60 years of age. ICARE analyses were adjusted for
sex, age, smoking status, hypertension, MI before enroll- gment, statin use, and metformin use. The following vari-
ables were considered as potential covariates for the ICARE
analysis but ultimately were not included in the model:
length of time with diabetes, blood pressure medications,
and stroke.
For analyses stratified according to HbA1c, we used 6.5%
s the cutoff because this has been defined as the value
eading to a diagnosis of diabetes, as well as the level at
hich complications of diabetes arise, as established by the
nternational Expert Committee composed of members of
he American Diabetes Association, the European Associ-
tion for the Study of Diabetes, and the International
iabetes Federation (22).
ooled analysis. To pool the risk estimates from multiple
tudy cohorts, we used the weighted average of regression
stimates in a random-effects meta-analysis, testing for
eterogeneity (23). In addition to NHS and ICARE, we
earched Medline through March 2012 for published data
f Hp genotype and CVD in cohorts with results stratified
ccording to either HbA1c or diabetes status. We also
searched the reference lists from the limited number of
studies of Hp genotype in the literature. We found 1
suitable publication, and it was from the Strong Heart Study
(SHS) (24). The publication contained Hp genotype fre-
quencies for 206 CVD cases and 206 matched controls, and
we used these frequencies to calculate the unadjusted odds
ratio and 95% confidence intervals (CIs) for the SHS
sample. In the SHS sample, the endpoint was total CVD
(CHD and incident stroke events), but 85% of events
were CHD related. HbA1c concentrations were not avail-
able for all participants, but results were published according
to diabetes status, which served as a proxy for HbA1c: it has
been reported that in the SHS participants specifically, a
diabetes diagnosis has similar risk of CVD as the cutoff of
HbA1c 6.5% (25). SHS was a population-based prospective
ongitudinal study of CVD in American Indians. Detailed
escriptions of the SHS cohort, survey methods, and CVD
ase ascertainment and laboratory techniques have been
escribed previously (25).
esults
he NHS. Baseline characteristics of the NHS partici-
ants are described in Table 1 according to Hp rs#72294371
enotype and case status. The distribution of Hp phenotype
requencies was 15% (Hp1-1), 46% (Hp2-1), and 39%
Hp2-2) (data not shown), and the Hp genotype frequency
id not differ between cases and controls. Among cases but
ot controls, Hp1-1 participants were significantly older
han those with the Hp2-1 or Hp2-2 genotype. As expected
ased on previous reports from this cohort (26), cases and
ontrols differed with respect to classic cardiovascular risk
actors (data not shown). When adjusted for covariates and
ase-control status, serum low-density lipoprotein (LDL)
holesterol was the only biomarker to differ across Hp
enotypes (p  0.05), with lower concentrations in Hp1-1
Baseline Characteristics by Hp Genotype and Case Status Among Women Age 44 to 69 Years at Blood Draw From a Nested Case-Control Study of CHD Eventsin the NHS, 1990 to 2004Table 1 B seline Characteristics by Hp Genotype nd Case Status Among Women Age 44 to 69 Years at Bl od Draw From a Nested Case-Control Study of CHD Eventsin the NHS, 1990 to 2004
Characteristic
Cases Controls
Hp1-1 (n  58) Hp2-1 (n  188) Hp2-2 (n  161) p Value Hp1-1 (n  66) Hp2-1 (n  189) Hp2-2 (n  156) p Value
Age* (yrs) 62.1 6.3 59.3 6.4 59.4 6.6 0.01 60.8 5.9 59.5 6.7 59.5 6.5 0.33
Smoking status*
Never 27 (47) 63 (34) 54 (34) 0.44 26 (39) 66 (35) 55 (35) 0.83
Past 18 (31) 74 (39) 62 (38) 21 (32) 75 (40) 62 (40)
Current 13 (22) 51 (27) 45 (28) 19 (29) 48 (25) 39 (25)
BMI (kg/m2) 26.1 (24.9–27.4) 26.0 (25.3–26.7) 26.1 (25.3–26.9) 0.97 25.5 (24.5–26.5) 24.7 (24.1–25.3) 25.0 (24.4–25.6) 0.39
Activity (MET h/week) 9.2 (6.3–13.5) 7.4 (6.0–9.17) 9.8 (7.8–12.3) 0.20 10.7 (7.9–14.6) 9.6 (8.03–11.6) 11.9 (9.77–14.6) 0.30
Alcohol (g/day) 2.46 (1.58–3.82) 4.88 (3.97–6.00) 4.16 (3.31–5.24) 0.02 4.83 (3.42–6.81) 4.45 (3.59–5.51) 5.10 (4.09–6.35) 0.68
Parental MI 60 yrs of age 9 (16) 41 (22) 32 (20) 0.58 7 (11) 22 (12) 25 (16) 0.39
History of hypercholesterolemia 25 (43) 96 (51) 99 (61) 0.03 22 (33) 79 (42) 63 (40) 0.48
History of hypertension 30 (52) 94 (50) 82 (51) 0.97 18 (27) 47 (25) 46 (29) 0.63
History of diabetes 10 (17) 24 (13) 24 (15) 0.66 4 (6) 13 (7) 7 (5) 0.64
Oral diabetic drug use 2 (3) 13 (7) 5 (3) 0.01 0 (0) 2 (1) 2 (1) 0.18
Cholesterol-lowering drug use 1 (2) 8 (4) 13 (8) 0.12 1 (2) 4 (2) 5 (3) 0.70
Post-menopausal hormone use† 17 (29) 59 (31) 50 (31) 0.43 24 (36) 60 (32) 59 (38) 0.83
CRP (mg/l) 0.30 (0.22–0.41) 0.24 (0.20–0.28) 0.26 (0.21–0.31) 0.36 0.19 (0.15–0.25) 0.19 (0.16–0.22) 0.16 (0.14–0.19) 0.49
Triglycerides (mg/dl) 129.5 (113.7–147.6) 121.4 (112.9–130.5) 123.1 (113.8–133.1) 0.69 107.4 (95.7–120.5) 105.4 (98.5–112.9) 104.3 (96.7–112.4) 0.92
HbA1c (%) 5.96 (5.69–6.24) 5.76 (5.61–5.91) 5.76 (5.62–5.94) 0.43 5.46 (5.33–5.59) 5.53 (5.45–5.61) 5.43 (5.34–5.51) 0.23
HbA1c 6.5% 10 (17) 23 (40) 25 (43) 0.001 3 (22) 9 (64) 2 (14) 0.01
Total cholesterol (mg/dl) 228 53 232 37 237 40 0.33 222 35 227 42 229 40 0.54
HDL cholesterol (mg/dl) 53 14 52 15 52 15 0.89 60 18 59 16 60 17 0.90
LDL cholesterol (mg/dl) 139 50 143 33 147 36 0.29 130 32 136 40 137 35 0.42
Apolipoprotein B (mg/dl) 111 36 114 34 116 33 0.68 104 33 103 30 107 30 0.45
Adiponectin (ng/ml) 7,142 (6,325–8,064) 7,125 (6,661–7,623) 7,515 (6,986–8,083) 0.54 8,355 (7,553–9,245) 8,541 (8,045–9,066) 8,649 (8,099–9,240) 0.85
Values are mean  SD, n (%), or geometric mean (95% confidence interval [CI]). Participant characteristics were compared between genotypes by using a general linear model for continuous variables and chi-square tests for categorical variables, unless there was a cell
with n 5, in which case the Fisher exact test was used. For skewed variables (physical activity, alcohol, high sensitivity C-reactive protein [CRP], body mass index [BMI], glycosylated hemoglobin [HbA1c], triglycerides, and adiponectin), p values from log-transformed analyses
and geometric means with reverse-transformed 95% CIs are displayed. *Case-control matching variable (also matched for fasting status and date at blood draw). †In post-menopausal women only.
CHD  coronary heart disease; HDL  high-density lipoprotein; Hp  haptoglobin; LDL  low-density lipoprotein; NHS  Nurses’ Health Study.
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(140  2 mg/dl) and Hp2-2 individuals (143  2 mg/dl)
(Online Table 1).
Table 2 presents the multivariate RR of CHD for the
Hp2-2 genotype compared with the Hp1 allele carriers.
Among all Hp2-2 carriers, the RR of CHD was 1.02 (95%
CI: 0.76 to 1.36) compared with Hp1 allele carriers (Hp 1-1
and Hp2-1 genotypes). We further stratified the data
according to known CHD risk factors. Among participants
with HbA1c 6.5% (n  72), the RR for Hp2-2 was 10.12
95% CI: 1.08 to 94.97), whereas no association for Hp
enotype was observed among participants with HbA1c
status6.5% (p for interaction 0.04). We did not observe
a similar interaction for reported diabetes history, but 38%
of the women with diabetes had HbA1c 6.5%. Because
only 24 participants reported using oral diabetic medication,
we could not conduct an analysis further stratified according
to medication use.
Figure 1A shows the joint effects of HbA1c level and Hp
enotype. Among women with Hp2-2 genotype and ele-
ated HbA1c, the RR of a CHD event was 10.72 (95% CI:
.46 to 46.77) compared with participants with an Hp1
llele and HbA1c 6.5%. Compared with this same
reference group, participants with the Hp2-2 genotype
who had HbA1c 6.5% were not at increased risk of
HD (RR: 0.95 [95% CI: 0.70 to 1.28]), and partici-
Multivariate RR* of CHD With 95% CIs for Hp GStratified According to CVD Risk Factors, in a Nin Women Aged 44 to 69 Year at Blo d Draw F
Table 2
Multivariate RR* of CHD With 95%
Stratified According to CVD Risk Fa
in Women Aged 44 to 69 Years at
Characteristic
Hp1-1  Hp2-1
Ca/Co RR
All participants
Matching factors only 246/255 Ref.
Multivariate adjusted* 246/255 Ref.
Age at baseline
60 yrs 100/112 Ref.
60 yrs 146/143 Ref.
Smoking
Never 90/92 Ref.
Past 92/96 Ref.
Current 64/67 Ref.
Diabetes†
No 205/236 Ref.
Yes 41/19 Ref.
HbA1c
6.5% 213/243 Ref.
6.5% 33/12 Ref.
History of hypercholesterolemia
No 125/154 Ref.
Yes 121/101 Ref.
LDL concentrations
Normal (160 mg/dl) 173/193 Ref.
High (160 mg/dl) 73/62 Ref.
*Adjusted model included age, BMI, smoking status, alcohol intake, d
stratified by 1 of these variables. †For analysis of risk of CHD by diabe
before their CHD event, and controls were updated as having diabetes if diag
CI  confidence interval; CVD  cardiovascular disease; Ref.  reference;ants with an Hp1 allele but with elevated HbA1c had a
orderline increased risk (RR: 2.05 [95% CI: 0.99 to
.24]).
eplication in the ICARE Study. The distribution of Hp
enotype frequencies was 13% (Hp1-1), 55% (Hp2-1), and
2% (Hp2-2) in the ICARE dataset, and the only baseline
haracteristics that differed among the genotypes were age
nd smoking (Table 3). Compared with participants with
he Hp1-1 or Hp2-1 genotype, the multivariate RR of
HD for the Hp2-2 genotype was 6.76 (95% CI: 2.88 to
5.87) in this diabetic cohort. Although we had less power,
e stratified by similar risk factors as we did for the NHS
nalyses (Table 4). Among participants 69 years of age
mean age) at baseline, the RR for Hp2-2 was 13.72 (95%
I: 3.06 to 61.54) compared with Hp1 allele carriers,
hereas the corresponding RR for the older half of partic-
pants was 3.73 (95% CI: 1.27 to 11.01). Among diabetic
atients not taking metformin, the RR for CHD was 15.84
95% CI: 3.54 to 70.83) for the Hp2-2 genotype compared
ith the Hp1 allele carriers, and those taking metformin
ad an RR of 3.77 (95% CI: 1.26 to 11.30).
To confirm the interaction between Hp genotype and
lycemic control, we performed several additional analyses.
mong participants with elevated HbA1c (6.5%), the RR
for CHD was 7.55 (95% CI: 2.79 to 20.47) for Hp2-2
individuals compared with the Hp1 allele carriers, whereas
pes, Together andd Case-Control Study of CHDthe NHS, 1990 to 2004or Hp Geno ypes, Together and
, in a Nested Case-Control Study of CHD
Draw From the NHS, 1990 to 2004
Hp2-2
p for Interactiona/Co RR 95% CI
1/156 1.07 0.81–1.42 —
1/156 1.02 0.76–1.36 —
7/67 1.21 0.71–1.78 0.40
4/89 0.92 0.63–1.36
4/55 0.97 0.59–1.60 0.87
2/62 0.97 0.59–1.57
5/39 1.18 0.67–2.10
0/146 0.97 0.71–1.32 0.38
1/10 2.05 0.73–5.72
6/154 0.95 0.70–1.29 0.04
5/2 10.12 1.08–94.97
2/93 0.80 0.52–1.21 0.12
9/63 1.32 0.86–2.03
0/117 0.96 0.68–1.37 0.57
1/39 1.14 0.64–2.01
, history of hypercholesterolemia, and history of hypertension, unless
us, cases were updated as having diabetes if they developed diabetesenotyesteromCIs f
ctors
Blood
C
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7
8
5
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4
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3
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tes statnosed with diabetes before their matched case had a CHD event.
RR  relative risk; other abbreviations as in Table 1.
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February 19, 2013:728–37 Haptoglobin, HbA1c, and Coronary Heart Diseaseno significant effect of Hp genotype was observed among
participants with HbA1c 6.5% (p for interaction  0.61).
When grouped by the combination of Hp genotype and
HbA1c status, the RR for CHD was 9.95 (95% CI: 2.28 to
43.47) among those with Hp2-2 genotype and HbA1c
6.5%, compared with participants with an Hp1 allele and
HbA1c 6.5% (Fig. 1B). Compared with the same refer-
ence group, participants with an Hp1 allele and elevated
Figure 1 Multivariate RR of CHD Events
According to Hp Genotype and HbA1c Status
(A) A nested case-control study of coronary heart disease (CHD) in women
aged 44 to 69 years from the NHS (Nurses’ Health Study) (1990–2004),
adjusted for age, body mass index, smoking, alcohol, history of hypercholester-
olemia, and history of hypertension. (B) Men and women with diabetes aged
22 to 95 years from the ICARE study (2005–2006), adjusted for sex, age,
smoking status, hypertension, myocardial infarction before enrollment, statin
use, and metformin use. (C) ICARE and NHS pooled together. HbA1c  glycosy-
lated hemoglobin; Hp  haptoglobin; RR  relative risk.HbA1c were not at significantly increased risk of CHD (RR:.29 [95% CI: 0.25 to 6.79]). No sex-based differences in
esults were present.
ooled analysis. When the NHS and ICARE cohorts
ere pooled in a meta-analysis, participants with both the
p2-2 genotype and high HbA1c had a pooled RR of 10.33
95% CI: 3.64 to 29.28) compared with participants with
oth an Hp1 allele and HbA1c 6.5% (pooled p for
interaction  0.03) (Fig. 1C). We did not detect heteroge-
neity between the studies (p  0.94).
Based on the previously published SHS data (24), we
calculated that in the SHS participants, those with both the
Hp2-2 genotype and diabetes (as a proxy for elevated high
HbA1c because in SHS participants specifically, a diabetes
diagnosis has similar risk of CVD as the cutoff of 6.5% for
HbA1c) had an RR of 7.01 (95% CI: 3.49 to 14.06)
compared with participants with both an Hp1 allele and no
diabetes (Fig. 2). When results from the NHS, ICARE,
and SHS were combined, this same RR was 7.90 (95%
CI: 4.43 to 14.10; heterogeneity p  0.93, interaction
p  0.004).
Discussion
In 2 independent large prospective cohorts with a broad
range of HbA1c concentrations, we found that individuals
with the rs#72294371 Hp2-2 genotype and elevated HbA1c
(6.5%) had a 10-fold increased risk of CHD compared
with those with an Hp1 allele and HbA1c 6.5%. Partici-
ants with the Hp2-2 genotype and HbA1c6.5% were not
t increased risk of CHD, even in cases of clinically
iagnosed diabetes, thus demonstrating that the underlying
athophysiological effects associated with the impaired
unction of the Hp2-2 protein are greatest among individ-
als with HbA1c 6.5%, regardless of diabetes status.
esults from the previously reported SHS data support
dditional replication. To the best of our knowledge, no
ther studies have reported results examining Hp genotype,
bA1c, and risk of CHD.
Biological mechanism. Hp functions to block oxidation by
iron associated with hemoglobin (8), and striking differences
between the Hp genotypes in their ability to perform this
function in the setting of hyperglycemia have been demon-
strated both in vitro and in vivo (Fig. 3). In vitro, this
functional discrepancy is due to a decreased ability of the
Hp2-2 protein to stabilize heme in the heme pocket of
HbA1c (6,27). In vivo, both in hyperglycemic animal models
and humans, those with the Hp2-2 genotype fail to effi-
ciently clear the Hp2-2–hemoglobin complex via the
monocyte/macrophage CD163 Hp–hemoglobin scavenger
receptor, resulting in increased plasma redox active iron.
Diabetic individuals with the Hp2-2 genotype may be at
increased risk of CHD from this increase in plasma redox
active Hp–hemoglobin complex if it binds to HDL levels
and thus results in the oxidative modification and loss of
I) or co
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transport. This hypothesis is supported by evidence dem-
onstrating that the HDL levels of Hp2-2 diabetic individ-
uals are extensively oxidized, and antioxidant therapy among
Hp2-2 diabetic individuals and mice prevents HDL oxida-
Baseline Characteristics According to Hp GenotWome With Diab tes Aged 22 to 95 Years FromTable 3 B selin Chara teristics According toWomen With Diabetes Aged 22 to 95
Characteristic Hp1-1 (n  270)
Sex 125 (46)
Age (yrs) 68.9 8.7
Smoking (yes) 16 (6)
Time since diabetes diagnosis (yrs) 8.9 (8.1–9.7)
Hypertension 199 (74)
Statin use 200 (74)
Metformin use 213 (79)
HbA1c (%) 7.18 (7.04–7.33)
Total cholesterol (mg/dl) 189 33
LDL cholesterol (mg/dl) 103 24
HDL cholesterol (mg/dl) 46 11
MI before study 31 (11)
MI during follow-up 3 (1)
CHD death during follow-up 0 (0)
Total CHD event† 3 (1)
Values are n (%), mean SD, or geometric mean (95% CI). *Participan
model for continuous variables and chi-square tests for categorical var
was used. For skewed variables (time since diabetes diagnosis and
reverse-transformed 95% CIs are displayed. †Myocardial infarction (M
Abbreviations as in Table 1.
Multivariate RR* of CHD Event with 95% CIs foStratified by CVD Risk Factors, in a ProspectiveAge 22 to 95 Years From the ICARE Study, 200
Table 4
Multivariate RR* of CHD Event with
Stratified by CVD Risk Factors, in a
Age 22 to 95 Years From the ICAR
Characteristic
Hp1-1  Hp2-1
Event/No Event RR E
All participants
Unadjusted 7/1405 Ref.
Multivariate adjusted 7/1405 Ref.
Age at baseline
69 yrs 2/716 Ref.
69 yrs 5/689 Ref.
Previous MI
No 5/1218 Ref.
Yes 2/187 Ref.
Smoking
No 5/1284 Ref.
Yes 2/121 Ref.
HbA1c
6.5% 2/406 Ref.
6.5% 5/999 Ref.
Years with diabetes
8 yrs 5/791 Ref.
8 yrs 2/614 Ref.
Metformin use
No 2/312 Ref.
Yes 5/1093 Ref.
*A proportional hazards model was used, adjusted for sex, age, smok
stratified by 1 of these variables.
Abbreviations as in Tables 1, 2, and 3.tive modification and restores HDL function (27). Hp
genotype is linked to CHD by additional mechanisms that
may be exacerbated by chronically high blood glucose. For
example, Hp motivates microangiogenesis (28,29), and
because the Hp1-1 genotype has the highest Hp concen-
mong Men andCARE Study, 2005 to 2006*Genotype Amo g Men and
rs From the ICARE Study, 2005 to 2006*
p2-1 (n  1,142) Hp2-2 (n  658) p Value
535 (47) 317 (48) 0.82
68.2 8.8 69.6 8.1 0.007
107 (9) 84 (13) 0.004
8.4 (8.0–8.8) 8.6 (8.1–9.1) 0.52
857 (75) 496 (75) 0.86
882 (77) 509 (77) 0.51
885 (78) 511 (78) 0.88
7.24 (7.18–7.33) 7.26 (7.16–7.35) 0.67
186 37 187 34 0.50
102 29 103 26 0.83
46 11 46 11 0.61
158 (14) 96 (15) 0.46
4 (1) 17 (3) 0.0001
0 (0) 5 (1) 0.003
4 (1) 22 (3) 0.0001
cteristics were compared between genotypes by using a general linear
unless there was a cell with n 5, in which case the Fisher exact test
p values from log-transformed analyses and geometric means with
ronary heart disease (CHD) death during follow-up.
Genotypes, Together andy of Diabetic Men and Women2006CIs for Hp Genotypes, T gether and
pective Study of Diabetic Men and Women
dy, 2005 to 2006
Hp2-2
p for InteractionNo Event RR 95% CI
636 6.83 2.92–15.98 —
636 6.76 2.88–15.87 —
289 13.72 3.06–61.54 0.16
347 3.73 1.27–11.01
547 6.39 2.30–17.74 0.89
89 8.23 1.68–40.46
557 7.64 2.81–20.75 0.57
79 4.50 0.80–25.30
184 4.30 0.77–24.01 0.61
452 7.55 2.79–20.47
366 4.59 1.58–13.29 0.39
270 12.74 2.71–58.75
134 15.84 3.54–70.83 0.16
502 3.77 1.26–11.30
tus, hypertension, previous MI, statin use, and metformin use, unlessype Ath IHp
Yea
H
t chara
iables,
HbA1c),r HpStud5 o95%
Pros
E Stu
vent/
22/
22/
12/
10/
15/
7/
17/
5/
4/
18/
11/
17/
13/
9/
ing sta
1
l
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to a better developed collateral circulation (18).
In the NHS, Hp genotype was associated with LDL
cholesterol concentrations. Some previous studies (30),
although not all (31), have found a similar association
between Hp genotype and cholesterol concentrations. We
did not observe an association in the ICARE analysis, but
this cohort was limited to diabetic individuals only, the
majority of who were receiving cholesterol-lowering medi-
cation. If an association between Hp genotype and LDL
cholesterol exists, it may be due to linkage disequilibrium
because the Hp gene is located in close proximity to the
lecithin-cholesterol acyltransferase and cholesteryl ester
transfer protein genes (32). However, in that case, we would
expect to detect a difference in HDL concentrations among
the Hp genotypes, which we did not observe.
Implications. Large randomized controlled trials of inten-
sive glycemic control therapy among diabetic individuals
have found significant reduction in cardiovascular outcomes
in some (11), but not all (12,33), cohorts. This inconsistency
may be due in part to different unknown characteristics
among patient subgroups that have not yet been explored, as
suggested in a meta-analysis of such trials by Ray et al. (34).
The Hp genotype frequencies differ among populations (35)
and may potentially explain differences in efficacy of glyce-
mic control reported in the literature. Replication in a
randomized trial of glycemic control, such as the ACCORD
Figure 2 RR of CHD Event According to Hp Genotype
and HbA1c Status in Studies to Date
In a nested case-control study of CHD in women from the NHS, in men and
women with diabetes from the ICARE study, in a nested case-control study of
cardiovascular disease (CVD) in men and women from the Strong Heart Study
(SHS) in which diabetes status serves as a proxy for HbA1c 6.5%, and in all
3 studies pooled together (in the pooled analysis, the p for interaction 
0.004). The NHS analysis used logistic regression adjusted for age, body mass
index, smoking, alcohol, history of hypercholesterolemia, and history of hyper-
tension; the ICARE analysis used a proportional hazards model adjusted for
sex, age, smoking status, hypertension, myocardial infarction before enroll-
ment, statin use, and metformin use. The SHS analysis was unadjusted by
using abstracted data (24). Abbreviations as in Figure 1.(Action to Control Cardiovascular Risk in Diabetes) studyor the DCCT (Diabetes Control and Complications Trial),
is required to confirm this finding. If replicated, Hp
genotyping could potentially assist in identifying genetically
susceptible individuals who would most benefit from clinical
management of HbA1c in the prevention of CHD.
Study strengths and limitations. Strengths of the CURRENT
analysis include comprehensive data gathered prospectively
with a long duration of follow-up, replication in a second
cohort, and a validated Hp genotyping method. The avail-
ability of results from a third and previously published study
extends the validity of the analysis, although further confir-
mation in larger cohorts is warranted, especially because the
ICARE and SHS cohorts had a limited number of incident
CHD cases, and in the pooled analysis in the current study,
the majority of cases were derived from the NHS. The RR
calculated for the SHS was not multivariate adjusted.
However, there is little confounding and attenuation of the
multivariate RR in the NHS and ICARE analyses; there-
fore, the crude RR for the SHS was likely minimally biased
by confounding factors. The current study may have been
underpowered to detect interactions between Hp genotype
and CHD risk factors. Furthermore, for biomarkers as-
sessed in stored plasma, such as HbA1c, we only had a single
measurement at baseline. Thus, random error caused by
normal fluctuations over time would cause underestimation
of true RRs. However, HbA1c reflects glycemic control over
an average of the 90-day red blood cell lifespan and is less
susceptible to daily changes. We found intraclass correla-
tions of 0.73 for repeated HbA1c samples measured 3 years
apart, which suggests good within-person reproducibility.
Conclusions
In 2 independent cohorts, we observed that participants
with both the Hp2-2 genotype and an HbA1c 6.5% had a
0-fold increased risk of CHD compared with those with at
east 1 Hp1 allele and HbA1c 6.5%. This finding, if
further replicated in studies such as ACCORD or DCCT,
may help explain inconsistencies in the literature for the
association of glycemic control with CVD outcomes, as well
as inconsistencies in previous studies of Hp genotype and
CHD. If replicated, Hp genotyping could potentially assist
in targeting cost-efficient clinical management of diabetes
among the most genetically sensitive individuals.
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